US2013064800A1PendingUtilityA1

Tissue-Engineered Endothelial and Epithelial Implants Differentially and Synergistically Regulate Tissue Repair

Assignee: EDELMAN ELAZER RPriority: Nov 6, 2007Filed: Aug 10, 2012Published: Mar 14, 2013
Est. expiryNov 6, 2027(~1.3 yrs left)· nominal 20-yr term from priority
A61P 9/00C12N 2501/115C12N 2501/385A61K 35/36A61P 17/02A61P 15/00C12N 2500/38C12N 2533/00A61P 11/00A61K 35/12C12N 2501/81C12N 2501/395C12N 2501/25C12N 2501/39C12N 2533/54A61L 27/3808A61K 35/42C12N 2501/11A61P 1/00C12N 2502/28C12N 5/0688
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Endothelial implants restore vascular homeostasis after injury without reconstituting vascular architecture. Endothelial cells line the vascular epithelium and underlying vasa vasorum precluding distinction between cellular controls. Unlike blood vessels, the airway epithelium is highly differentiated and distinct from endothelial cells that line the bronchial vasa allowing investigation of the differential control tissue engineered cells may provide in airways and blood vessels. Through airway injury and cell culture models, tissue engineered implants of the bronchial epithelium and endothelium were found to promote synergistic repair of the airway through biochemical regulation of the airway microenvironment. While epithelial cells modulate local tissue composition and reaction, endothelial cells preserve the epithelium; together their relative impact was enhanced suggesting both cell types act synergistically for airway repair.

Claims

exact text as granted — not AI-modified
1 .- 52 . (canceled) 
     
     
         53 . A method of effecting localized repair of injury to a multilaminate tubular structure, said method comprising the step of:
 providing a composition comprising endothelial cells and epithelial cells wherein the composition, when administered to a non-luminal surface of an injured tubular structure, promotes vascular functionality in the vicinity of the injury while simultaneously promoting epithelial functionality within the luminal epithelium in the vicinity of the injury.   
     
     
         54 . The method of  claim 53  wherein the composition promotes vascular functionality within the vasa vasorum in the vicinity of the injury. 
     
     
         55 . The method of  claim 53  wherein the cells are autogenic, allogenic, or xenogenic. 
     
     
         56 . The method of  claim 53  wherein the composition further comprises a biocompatible matrix which is biodegradable. 
     
     
         57 . The method of  claim 56  wherein the biocompatible matrix is a flexible planar material or a flowable composition. 
     
     
         58 . The method of  claim 57  wherein the flexible planar material is a solid polymeric support or a fibrous structure. 
     
     
         59 . The method of  claim 57  wherein the flowable composition comprises particles, beads, gels, foams, suspensions or microcapsules or combinations of any one of the foregoing. 
     
     
         60 . The method of  claim 56  wherein the biocompatible matrix is formed of a material selected from the group consisting of polyhydroxy acids, polyorthoesters, polyanhydrides, proteins, polysaccharides, polyphosphazenes and combinations of any one of the foregoing. 
     
     
         61 . The method of  claim 56  wherein the biocompatible matrix is formed of a material selected from the group consisting of ethylene vinyl acetate, polyvinyl alcohol, silicone, polyurethane, non-biodegradable polyesters, polyethyleneoxide-polypropyleneoxide, tetrafluoroethylene and combinations of any one of the foregoing.

Join the waitlist — get patent alerts

Track US2013064800A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.